title: Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies.
abstract: Many patients who receive co-treatment with GnRH agonists (GnRH-a) during chemotherapy treatment preserve their ovarian function and are at risk of unintended pregnancies. Therefore, it is important to offer them effective contraception. Also, pregnancies occurring after cancer therapy in women who received GnRH-a are not associated with adverse neonatal outcomes.
authors.affiliation: Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. Electronic address: castelobranco@ub.edu.
authors.forename: Camil
authors.initials: C
authors.lastname: Castelo-Branco
authors.affiliation: Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Aintzane
authors.initials: A
authors.lastname: Rabanal
authors.affiliation: Institut Clínic de Malalties Hematològiques i Oncològiques, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Benet
authors.initials: B
authors.lastname: Nomdedeu
authors.affiliation: Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Magda
authors.initials: M
authors.lastname: Durán
authors.affiliation: Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Marta
authors.initials: M
authors.lastname: Arigita
authors.affiliation: Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Balasch
mesh_terms: D000293:Adolescent; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D016022:Case-Control Studies; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D008875:Middle Aged; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000453:epidemiology; D011256:Pregnancy Outcome; D049168:Pregnancy, Unplanned; D016649:Primary Ovarian Insufficiency / Q000517:prevention & control*; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014747:Vinblastine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D001761:Bleomycin; D007987:Gonadotropin-Releasing Hormone; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin